BioNTech’s cash and securities nearly equal its market value, meaning investors aren’t paying much for the Covid franchise ...

If you are wondering whether BioNTech is starting to look like value after the Covid vaccine boom faded, or if the current price still feels rich, this article walks through what the numbers actually ...

Nothing about the recent past, present, or foreseeable future seems all that compelling.

BioNTech SE BNTX shares are down during Tuesday’s premarket session as the company announced plans for its co-founders to transition into a new venture focused on next-generation mRNA innovations.

BioNTech (NasdaqGS:BNTX) cofounders Ugur Sahin and Özlem Türeci are leaving their roles as CEO and Chief Medical Officer. Both executives plan to launch a new startup, triggering a leadership ...

The German biotech provides a weak full-year outlook and announces the exit of its co-founders.

BioNTech (BNTX) shares fell over 20% after the company reported an earnings miss and announced plans for its founders to ...

BioNTech (BNTX) reported upbeat Q4 results and FY26 sales guidance below estimates. Shares gained 7.7% on Wednesday. Analysts have mixed opinions.

BioNTech SE Sponsored ADR (BNTX) shares rallied 11.8% in the last trading session to close at $118. This move can be attributable to notable volume with a higher number of shares being traded than in ...